Cargando…
Deoxynivalenol and Its Modified Forms: Are There Major Differences?
Considering the diverse toxic effects of the Fusarium toxin deoxynivalenol (DON), its common occurrence in wheat-based products, and its stability during processing, DON constitutes an increasing health concern for humans and animals. In addition to the parent compound DON, human and animal exposure...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127130/ https://www.ncbi.nlm.nih.gov/pubmed/27854268 http://dx.doi.org/10.3390/toxins8110334 |
_version_ | 1782470216914042880 |
---|---|
author | Alizadeh, Arash Braber, Saskia Akbari, Peyman Kraneveld, Aletta Garssen, Johan Fink-Gremmels, Johanna |
author_facet | Alizadeh, Arash Braber, Saskia Akbari, Peyman Kraneveld, Aletta Garssen, Johan Fink-Gremmels, Johanna |
author_sort | Alizadeh, Arash |
collection | PubMed |
description | Considering the diverse toxic effects of the Fusarium toxin deoxynivalenol (DON), its common occurrence in wheat-based products, and its stability during processing, DON constitutes an increasing health concern for humans and animals. In addition to the parent compound DON, human and animal exposure encompasses the acetylated fungal metabolites 3-acetyl-deoxynivalenol (3ADON) and 15-acetyl-deoxynivalenol (15ADON) as well as the plant-derived DON-glucoside (DON3G) and the bacterial product de-epoxy-DON (DOM-1). In the current study we used the well-established Caco-2 cell model to compare the effects of these naturally occurring forms of DON on cell viability and markers of barrier integrity, as well as on the release of the pro-inflammatory chemokine chemokine CXC motif ligand (CXCL8). Results show that 3ADON is less potent in inducing adverse effects on barrier integrity when compared to DON, whereas 15ADON appears to be slightly more potent than DON. In contrast, DON3G and DOM-1 exerted no measurable adverse effects on the intestinal barrier. It was also demonstrated that galacto-oligosaccharides (GOS) are able to protect epithelial cells against DON and its acetylated forms, which suggests that GOS are beneficial food additives in the protection of vulnerable segments of the human population against adverse effects of DON and its derivatives. |
format | Online Article Text |
id | pubmed-5127130 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-51271302016-12-02 Deoxynivalenol and Its Modified Forms: Are There Major Differences? Alizadeh, Arash Braber, Saskia Akbari, Peyman Kraneveld, Aletta Garssen, Johan Fink-Gremmels, Johanna Toxins (Basel) Article Considering the diverse toxic effects of the Fusarium toxin deoxynivalenol (DON), its common occurrence in wheat-based products, and its stability during processing, DON constitutes an increasing health concern for humans and animals. In addition to the parent compound DON, human and animal exposure encompasses the acetylated fungal metabolites 3-acetyl-deoxynivalenol (3ADON) and 15-acetyl-deoxynivalenol (15ADON) as well as the plant-derived DON-glucoside (DON3G) and the bacterial product de-epoxy-DON (DOM-1). In the current study we used the well-established Caco-2 cell model to compare the effects of these naturally occurring forms of DON on cell viability and markers of barrier integrity, as well as on the release of the pro-inflammatory chemokine chemokine CXC motif ligand (CXCL8). Results show that 3ADON is less potent in inducing adverse effects on barrier integrity when compared to DON, whereas 15ADON appears to be slightly more potent than DON. In contrast, DON3G and DOM-1 exerted no measurable adverse effects on the intestinal barrier. It was also demonstrated that galacto-oligosaccharides (GOS) are able to protect epithelial cells against DON and its acetylated forms, which suggests that GOS are beneficial food additives in the protection of vulnerable segments of the human population against adverse effects of DON and its derivatives. MDPI 2016-11-16 /pmc/articles/PMC5127130/ /pubmed/27854268 http://dx.doi.org/10.3390/toxins8110334 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Alizadeh, Arash Braber, Saskia Akbari, Peyman Kraneveld, Aletta Garssen, Johan Fink-Gremmels, Johanna Deoxynivalenol and Its Modified Forms: Are There Major Differences? |
title | Deoxynivalenol and Its Modified Forms: Are There Major Differences? |
title_full | Deoxynivalenol and Its Modified Forms: Are There Major Differences? |
title_fullStr | Deoxynivalenol and Its Modified Forms: Are There Major Differences? |
title_full_unstemmed | Deoxynivalenol and Its Modified Forms: Are There Major Differences? |
title_short | Deoxynivalenol and Its Modified Forms: Are There Major Differences? |
title_sort | deoxynivalenol and its modified forms: are there major differences? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127130/ https://www.ncbi.nlm.nih.gov/pubmed/27854268 http://dx.doi.org/10.3390/toxins8110334 |
work_keys_str_mv | AT alizadeharash deoxynivalenolanditsmodifiedformsaretheremajordifferences AT brabersaskia deoxynivalenolanditsmodifiedformsaretheremajordifferences AT akbaripeyman deoxynivalenolanditsmodifiedformsaretheremajordifferences AT kraneveldaletta deoxynivalenolanditsmodifiedformsaretheremajordifferences AT garssenjohan deoxynivalenolanditsmodifiedformsaretheremajordifferences AT finkgremmelsjohanna deoxynivalenolanditsmodifiedformsaretheremajordifferences |